Legend Biotech Corp (LEGN)
40.94
+1.19
(+2.99%)
USD |
NASDAQ |
Nov 22, 16:00
40.95
+0.01
(+0.02%)
After-Hours: 20:00
Legend Biotech Enterprise Value: 6.595B for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 6.595B |
| November 21, 2024 | 6.376B |
| November 20, 2024 | 6.448B |
| November 19, 2024 | 6.129B |
| November 18, 2024 | 5.949B |
| November 15, 2024 | 6.090B |
| November 14, 2024 | 6.402B |
| November 13, 2024 | 6.303B |
| November 12, 2024 | 6.455B |
| November 11, 2024 | 6.430B |
| November 08, 2024 | 6.428B |
| November 07, 2024 | 6.597B |
| November 06, 2024 | 6.677B |
| November 05, 2024 | 7.270B |
| November 04, 2024 | 7.084B |
| November 01, 2024 | 7.222B |
| October 31, 2024 | 7.343B |
| October 30, 2024 | 7.206B |
| October 29, 2024 | 7.424B |
| October 28, 2024 | 7.395B |
| October 25, 2024 | 7.292B |
| October 24, 2024 | 7.167B |
| October 23, 2024 | 7.147B |
| October 22, 2024 | 7.346B |
| October 21, 2024 | 7.055B |
| Date | Value |
|---|---|
| October 18, 2024 | 6.949B |
| October 17, 2024 | 6.989B |
| October 16, 2024 | 7.160B |
| October 15, 2024 | 7.323B |
| October 14, 2024 | 8.198B |
| October 11, 2024 | 8.257B |
| October 10, 2024 | 8.304B |
| October 09, 2024 | 8.044B |
| October 08, 2024 | 7.901B |
| October 07, 2024 | 8.180B |
| October 04, 2024 | 8.086B |
| October 03, 2024 | 7.851B |
| October 02, 2024 | 8.015B |
| October 01, 2024 | 7.794B |
| September 30, 2024 | 8.024B |
| September 27, 2024 | 8.080B |
| September 26, 2024 | 7.634B |
| September 25, 2024 | 7.025B |
| September 24, 2024 | 7.341B |
| September 23, 2024 | 7.462B |
| September 20, 2024 | 7.943B |
| September 19, 2024 | 8.367B |
| September 18, 2024 | 8.198B |
| September 17, 2024 | 8.430B |
| September 16, 2024 | 8.395B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.627B
Minimum
Mar 04 2021
12.94B
Maximum
Jun 22 2023
6.950B
Average
6.884B
Median
Dec 09 2021
Enterprise Value Benchmarks
| Johnson & Johnson | 389.04B |
| Ligand Pharmaceuticals Inc | 2.032B |
| CEL-SCI Corp | 36.25M |
| AIM ImmunoTech Inc | 8.915M |
| IGC Pharma Inc | 26.16M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -125.32M |
| Revenue (Quarterly) | 160.20M |
| Total Expenses (Quarterly) | 230.26M |
| EPS Diluted (Quarterly) | -0.70 |
| Gross Profit Margin (Quarterly) | 65.38% |
| Profit Margin (Quarterly) | -78.23% |
| Earnings Yield | -4.69% |
| Normalized Earnings Yield | -5.199 |